Needham & Company Starts BioTelemetry (BEAT) at Buy
Tweet
Share
E-mailGet Alerts BEAT Hot Sheet
Price: $0.58 +1.75%
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
8 Buy, 7 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Needham & Company analyst Mike Matson initiates coverage on BioTelemetry (NASDAQ: BEAT) with a Buy rating and a price target of $52.00.
For an analyst ratings summary and ratings history on BioTelemetry click here. For more ratings news on BioTelemetry click here.
Shares of BioTelemetry closed at $36.67 yesterday.
You May Also Be Interested In
- Raymond James Starts Polaryx Therapeutics (PLYX) at Strong Buy
- Benchmark Starts Allegro MicroSystems (ALGM) at Buy
- Citi Starts Sibyane Stillwater (SBSW) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
